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Distinct Clinical Phenotypes Associated with a Mutation
in the Mitochondrial Translation Elongation Factor EFTs
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Brigitte Welling, Ju¨rgen Horst, Richard J. Rodenburg, Bert van den Heuvel, and Eric A. Shoubridge
The 13 polypeptides encoded in mitochondrial DNA (mtDNA) are synthesized in themitochondrial matrix on a dedicated
protein-translation apparatus that resembles that found in prokaryotes. Here, we have investigated the genetic basis for
a mitochondrial protein-synthesis defect associated with a combined oxidative phosphorylation enzyme deﬁciency in
two patients, one of whom presented with encephalomyopathy and the other with hypertrophic cardiomyopathy.
Sequencing of candidate genes revealed the same homozygous mutation (C997T) in both patients in TSFM, a gene coding
for the mitochondrial translation elongation factor EFTs. EFTs functions as a guanine nucleotide exchange factor for
EFTu, another translation elongation factor that brings aminoacylated transfer RNAs to the ribosomal A site as a ternary
complex with guanosine triphosphate. The mutation predicts an Arg333Trp substitution at an evolutionarily conserved
site in a subdomain of EFTs that interacts with EFTu. Molecular modeling showed that the substitution disrupts local
subdomain structure and the dimerization interface. The steady-state levels of EFTs and EFTu in patient ﬁbroblasts were
reduced by 75% and 60%, respectively, and the amounts of assembled complexes I, IV, and V were reduced by 35%–
91% compared with the amounts in controls. These phenotypes and the translation defect were rescued by retroviral
expression of either EFTs or EFTu. These data clearly establish mutant EFTs as the cause of disease in these patients. The
fact that the same mutation is associated with distinct clinical phenotypes suggests the presence of genetic modiﬁers of
the mitochondrial translation apparatus.
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Defects in mitochondrial oxidative phosphorylation (OX-
PHOS) are estimated to occur in ∼1 in 5,000 live births.1
They can be classiﬁed biochemically as either isolated or
combined deﬁciencies of any of the ﬁve OXPHOS com-
plexes.2 Genetic defects leading to combined deﬁciencies
of complexes I, III, IV, and V can be caused by mutations
in mtDNA or in the components of the mitochondrial
translation apparatus encoded by nuclear genes.3
Synthesis of the 13 mitochondrial-encoded proteins oc-
curs on a dedicated mitochondrial translation apparatus
similar to that found in prokaryotes and requires, in ad-
dition to the tRNAs and ribosomal RNAs (rRNAs) encoded
in mtDNA, the concerted action of several translation fac-
tors and a large number of mitochondrial ribosomal (mi-
toribosome) proteins, all of which are encoded by nuclear
genes. Twomammalian initiation factors, IF2 and IF3; four
elongation factors, EFTu, EFTs, EFG1, and EFG2 (reviewed
by Spremulli et al.4); one release factor, RF1; and one ri-
bosomal recycling factor, RRF,5 have been cloned and se-
quenced. Mitoribosomes are distinct from both prokar-
yotic and eukaryotic cytosolic ribosomes; they are 55S
particles composed of a small (28S) and a large (39S) sub-
unit and contain a much higher protein:RNA ratio than
that of the bacterial 70S ribosome.6
Although the vast majority of components of the mi-
tochondrial translation system are nuclear encoded, most
mutations associated with mitochondrial translation de-
fects have been reported in mtDNA-encoded tRNAs and
rRNAs.7,8 However, we recently reported mutations in the
nuclear-encoded translation elongation factor EFG19,10
and inMRPS16, a protein of the small ribosomal subunit,11
in patients with autosomal recessive mitochondrial trans-
lation defects. Encouraged by these ﬁndings, we investi-
gated a cohort of 16 patients with combined OXPHOS
enzyme defects expressed in both muscle and ﬁbroblasts
in which mtDNA sequencing and complex II activity–
measurement results were normal. We describe the ﬁrst
mutation in the mitochondrial elongation factor EFTs (en-
coded by TSFM [MIM 604723]) associated with a fatal mi-
tochondrial encephalomyopathy in one pedigree and
with fatal hypertrophic cardiomyopathy in another, and
we demonstrate the molecular basis for the defect.
Material and Methods
Case Reports
Patient 1, a boy, was born at term as the second child of consan-
guineous Turkish parents by cesarean section performed on ma-
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ternal indication. Birth weight (3,140 g), length (50 cm), andhead
circumference (36 cm) were age appropriate.Muscularhypotonia,
sucking weakness, and a severe lactic acidosis (pH 6.8; base excess
26; lactic acid 42mM [control !2.1mM]) were the initial clinical
signs and symptoms, followed by rhabdomyolysis with creatine
kinase values up to 7,252 U/liter (control !248 U/liter). The initial
lactate:pyruvate (L:P) ratio was 92 (control 12–15). During life,
lactic acid dropped to values between 4 and 5.5 mM, with L:P
ratios ∼25. Artiﬁcial ventilation was needed because of persistent
dyspnea. On the 3rd day of life, generalized convulsions became
obvious. The electroencephalogram showed a discontinuous pat-
tern with bifrontal symmetrical sharper spikes. Repeated ultra-
sound imaging of the brain showed reduced gyri on day 4, plexus
bleeding with enlarged ventricles on day 6, and abnormal signal
intensity of the thalami on day 9. Echocardiographic examina-
tion on day 6 revealed a persistent ductus arteriosus Botalli, with
left-to-right shunting, and a persistent foramen ovale. Septum
thickness and contractility were age appropriate. On the basis of
the suspicion of a mitochondrial disorder, a ﬁbroblast culturewas
established and a skeletal muscle (m. vastus lateralis dextra) bi-
opsy sample was obtained for measurements of the OXPHOS en-
zymes. Despite intensive treatment, the patient died of progres-
sive encephalomyopathy and respiratory failure at age 7 wk.
Patient 2, a girl, was the third child of second cousins once
removed whose parents are of Kurdish Jewish origin. Two older
children were healthy. The mother reported a paucity of fetal
movements throughout the pregnancy. Delivery was vaginal, and
birth weight was 2,600 g. Initial examination results were normal,
and the patient was breast-fed. At age 36 h, apathy, irregular
breathing, and severemuscular hypotoniawere noted. Laboratory
investigation revealed severe metabolic acidosis (pH 6.93; HCO3
4.6; base excess 26). Serum lactate level was increased (17.6
mM; control !2.4 mM), as were blood ketone levels (3-OH-
butyrate 4,803 mM; acetoacetate 257 mM; control values !200 mM
and !100 mM, respectively) and serum ammonia levels (268 mM;
control !32 mM). Blood count and liver enzyme levels were nor-
mal. Echocardiographic examination disclosed severe concentric
hypertrophic cardiomyopathy with normal contractility. Apart
from generalized muscle hypotonia, neurological examination,
including fundoscopy and brain CT scan, were normal. Skin bi-
opsy for ﬁbroblast culture andmuscle biopsy from the right quad-
riceps were performed at age 2 wk; histochemical analysis of the
muscle revealed a generally decreased cytochrome c oxidase
(COX) stain, whereas the succinate dehydrogenase stain was nor-
mal. The patient was given treatment with carnitine, sodium-
dichloroacetate, thiamine, idebenone, and riboﬂavin, but the lac-
tate level remained elevated, and cardiac function gradually
deteriorated. Her death at age 7 wk was preceded by severe hy-
ponatremia with a low urinary output for 2 d. An open-liver
biopsy was performed 20 min after her death.
Southern-blot analysis of the muscle, liver, and ﬁbroblast DNA
revealed normal size and abundance of mtDNA. Northern-blot
analysis showed that the steady-state levels of several mitochon-
drial transcripts (ND6, COXI, COXII, and 12S rRNA)were normal.
Sequencing of the 22 mitochondrial tRNA genes failed to identify
a pathogenic mutation.
Human Studies
Informed consent was obtained, and research studies were ap-
proved by the Helsinki committee of Hadassah–Hebrew Univer-
sity Medical Center, the Radboud University Medical Centre Nij-
megen, and the Montreal Neurological Institute Institutional
Review Boards.
Cell Culture
Primary human skin ﬁbroblasts were immortalized with a ret-
rovirus expressing the E7 gene of type 16 human papilloma virus
and a retroviral vector expressing the protein component (htert)
of human telomerase.12 Patient and control skin ﬁbroblasts were
cultured in Dulbecco’s modiﬁed Eagle medium (DMEM) supple-
mented with 10% fetal calf serum.
Enzyme Measurements
The activities of the OXPHOS enzyme complexes in skeletal
muscle and ﬁbroblasts were measured according to described
protocols.13,14 COX and citrate synthase activities were measured
in ﬁbroblast cell extracts as described elsewhere.15
Sequence Analysis
Total RNA was extracted from cultured skin ﬁbroblasts of the
patients by use of RNAzol (Campro Scientiﬁc). The TSFM cDNA
(GenBank accession number NM_005726) was ampliﬁed by su-
perscript II reverse transcriptase/Taq DNA polymerase (Life Tech-
nologies) in four overlapping fragments (primer sequences avail-
able on request). After treatment with ExoI (Promega) and SAP
(Promega), the PCR fragments were used as templates in sequenc-
ing reactions with the chemistry of BigDye1.1 (Applied Biosys-
tems) according to the manufacturer’s protocol. The labeled frag-
ments were separated on a 3130xl Genetic Analyzer (Applied
Biosystems). Sequence data were evaluated with Sequencher 4.2
sequence-analysis software (Gene Codes) by comparison with the
reference sequence of TSFM. Sequence analysis of the last part of
exon 7 of the TSFM gene was performed on genomic DNA by use
of the primers 5′-CTTGGGCAGCCATGTGG-3′ (forward) and 5′-
ACCCATGCATTCTCGGTCTG-3′ (reverse).
Blue-Native PAGE and Immunoblotting
Blue-native PAGE was used for separation of the OXPHOS com-
plexes on 6%–15% polyacrylamide-gradient gels.16 Mitoplasts,
which were prepared from ﬁbroblasts by treatment with 0.8 mg
of digitonin per mg of protein, were solubilized with 1% lauryl
maltoside, and 20 mg of the solubilized protein was used for elec-
trophoresis.17 Assembly of the OXPHOS complexes was estab-
lished by immunoblot analysis with the use of monoclonal an-
tibodies against subunits of complexes II–V (Molecular Probes)
and a polyclonal antibody against the ND1 subunit of complex
I (a kind gift of A. Lombes, Paris). For immunoblotting,ﬁbroblasts
were solubilized with 1.5% lauryl maltoside in PBS, and 20 mg of
protein was separated by TRIS-Glycine SDS-PAGE gel. After trans-
fer to a nitrocellulose membrane, individual proteins were de-
tected using monoclonal antibodies against subunits of com-
plexes I–V (Molecular Probes), porin (Sigma), MnSOD (Stressgen),
and polyconal antibodies directed against ND1, EFTu (a kind gift
of N. Takeuchi, Tokyo), EFTu/Ts (a kind gift of L. Spremulli,
Chapel Hill, NC), and EFG1.10
Pulse Labeling of Mitochondrial Translation Products
In vitro labeling of mitochondrial translation was performed as
described elsewhere.18 In brief, cells were labeled for 60 min at
37C in methionine-free DMEM with 10% dialyzed fetal bovine
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Table 1. OXPHOS Enzyme Activities in Skeletal Muscle and
Fibroblasts of Patient 1
Complex
Activities (mU/U citrate synthase) in
Skeletal Muscle Fibroblasts
Patient Reference Range Patient Reference Range
I 0 70–250 53 100–310
III 753 2,200–6,610 1,250 1,320–2,610
II  III 228 300–970 163 110–470
IV 186 810–3,120 397 680–1,190
PDH 60 34–122 ND ND
NOTE.—Samples were 600 g of supernatant of skeletal muscle or mi-
tochondrial enriched fraction from ﬁbroblasts. ND p not determined;
PDHp pyruvate dehydrogenase complex.
Figure 1. Pulse labeling of mitochondrial translation products
in patient ﬁbroblasts. Fibroblasts from the two patients (P1 and
P2) and two controls (C1 and C2) were labeled with [35S]methionine
in the presence of emetine, a cytosolic translation inhibitor, as
outlined in the “Material and Methods” section. Fibroblasts from
patient 1 were also analyzed after transduction with retroviral
vectors overexpressing the mitochondrial translation factors EFTu
or EFTs. The mitochondrial translation products are indicated on
the left of the autoradiogram. COI–COIIIp subunits of cytochrome
c oxidase; cytb p cytochrome b subunit; ND1, ND2, ND3, ND4,
ND4L, ND5, and ND6 p subunits of NADH CoQ oxidoreductase.
The numbers at the bottom of the gel indicate the total incor-
poration of [35S]methionine relative to the corresponding control.
serum, containing 200 mCi/ml of [35S]methionine and 100 mg/ml
of emetine, followed by a 10-min incubation in regular DMEM
with 10% fetal bovine serum. Total cellular protein (50 mg) was
resuspended in loading buffer containing 93 mM Tris-HCl (pH
6.7), 7.5% glycerol, 1% SDS, 0.25 mg bromophenol blue per
ml, and 3% mercaptoethanol, was sonicated for 3–8 s, and was
run on 12%–20% polyacrylamide-gradient gels. The gels were
scanned on a Storm Phosphorimager (Molecular Dynamics) and
were analyzed with ImageQuant software. Under the conditions
of the experiment, all signals were in the linear range.
cDNA Constructs, Virus Production, and Infection
Retroviral vectors containing the cDNA sequence of TUFM (Gen-
Bank accession number NM_003321) and TSFMwere createdwith
the Gateway cloning system (Invitrogen) as described elsewhere.10
The PCR constructs were cloned into a Gateway-modiﬁed retro-
viral-expression vector (pBABE-puro). Retroviral constructs were
transiently transfected into Phoenix packaging cell line by use of
the HBS/Ca3(PO4)2 method (Helper Dependent ProtocolWeb site).
Patient and control ﬁbroblasts were infected 48 h later by ex-
posure to virus-containing medium in the presence of 4 mg/ml
of polybrene, as described elsewhere.12
Computational Modeling
The crystal structure of the bovine EFTu/EFTs complex has been
described elsewhere.19 On the basis of this model, the structure
of wild-type and mutant EFTs protein were determined with the
YASARA–WHAT IF twin set software.20 The R333W mutation was
predicted using the method of De Fillippis et al.21 Molecular ﬁg-
ures were drawn with the POV-Ray module in YASARA. Further
modeling details are available at the TS Modelling Web site.
Results
Skeletal muscle and ﬁbroblasts from patient 1 showed de-
creased enzyme activities of complexes I, III, and IV of the
respiratory chain (table 1). The activities of complexes I,
III, and IV in the skeletal muscle of patient 2 were similarly
reduced to 30%, 14%, and 14% of the control means,
respectively, whereas complex II was unaffected (123% of
the control mean). In ﬁbroblast mitochondria from pa-
tient 2, complexes I, IV, IIIII, and II activities were 44%,
25%, 77%, and 107% of the control mean, respectively.
Pulse labeling of the mitochondrial translation products
in ﬁbroblasts from both patients revealed a generalized
mitochondrial protein-synthesis defect; however, differ-
ent polypeptides were variably affected (ﬁg. 1 and table
2). The overall incorporation of [35S]methioninewas 39%–
49% of that in controls, and the rate of synthesis of most
polypeptides was reduced to 30%–60% of control values.
However, the synthesis of the two ATP synthase subunits
(ATP6 and ATP8) actually increased relative to control lev-
els in patient 1 and was similar to control levels in patient
2 (table 2).
These data suggested that the genetic defect was due to
a component of the mitochondrial translation apparatus,
and the failure to identify any abnormalities in mtDNA
(data not shown) suggested a nuclear gene defect. Two
strategies were employed to identify the underlying ge-
netic defect. In patient 1 (and 14 additional patients with
a similar combined OXPHOS deﬁciency), we sequenced
the cDNAs for the known mitochondrial translation ini-
tiation, elongation, and termination factors. In patient 2,
we used the Affymetrix Human Mapping 50K Array
Xba240 to genotype 58,495 SNPs to identify regions of
homozygosity. The latter analysis identiﬁed a long seg-
ment of consecutive homozygous SNPs on chromosome
2 spanning 22.1 Mb (213.1–235.2 Mb) and another seg-
ment on chromosome 12 spanning 30.79 Mb (26.48–
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Table 2. Synthesis of Individual Mitochondrial
Polypeptides in Fibroblasts from Patients P1 and P2
after Pulse Labeling with [35S]Methionine
Polypeptide
Incorporation of [35S]Methionine
(% of Control)
P1 P2 P1  EFTu P1  EFTs
ND5 22 18 59 49
COI 34 32 59 61
ND4 42 33 65 52
ND2/cytb 61 51 56 43
ND1 56 55 58 46
COIII/COII 42 34 56 60
ATP6 134 64 69 31
ND6 59 21 60 72
ND3 103 68 112 91
ND4L 29 30 43 48
ATP8 244 113 94 22
NOTE.—The results are presented as a percentage of the average in-
corporation of [35S]methionine in two relevant controls. Mitochondrial
translation was also analyzed in patient 1 after transduction with re-
troviral constructs overexpressing EFTu or EFTs. COI–COIII p subunits
of cytochrome c oxidase; cytb p cytochrome b subunit; ND1, ND2, ND3,
ND4, ND4L, ND5, and ND6 p subunits of NADH CoQ oxidoreductase.
57.27 Mb). With use of the MitoP2 prediction program22
for mitochondrial localization (score 160), two proteins
with known function in mitochondrial translation were
identiﬁed within these regions—the mitochondrial ribo-
somal protein S35 and themitochondrial translationelon-
gation factor EFTs (encoded by TSFM).
Sequence analysis of TSFM revealed the same homo-
zygous C997T mutation in exon 7 in both patients (ﬁg.
2). A BLAST search showed that the C997T mutation was
not present in any reported human EST, and themutation
was not found in the other 14 patients tested or in 135
controls. The mutation was heterozygous in the parents
in both families and in the two healthy sibs of patient 2
(data not shown). A sib of patient 1 was homozygous wild
type (data not shown). Analysis of microsatellite markers
on chromosome 12 demonstrated that the mutation did
not arise on a common haplotype in the two patients (ﬁg.
2D). Human TSFM appears to be alternatively spliced,
since exon 5 was not present in any of the patient or
control cDNAs analyzed. Exon 5 is present in a single EST
sequence in the human database, derived form bone mar-
row of a patient with acute myelogenous leukemia.
The mutation predicts an Arg333Trp substitution in the
C-terminal domain of EFTs, and sequence alignment of
this protein from several species shows that the mutated
amino acid is highly conserved from human to bacteria
(ﬁg. 2B). This Arg residue makes favorable hydrophobic
and electrostatic interactions within the helical part of
subdomain C (ﬁg. 3). Mutational analysis using the crystal
structure of the bovine EFTu•EFTs complex shows that it
is not possible to introduce a Trp at this position without
serious clashes between the Trp side chain and the back-
bone atoms in the immediate surroundings. The close-up
of the region of Ts that harbors the mutation shows three
preferred rotamers of Trp, representing three different en-
ergy minima (ﬁg. 3, lower panel). The rotamer that is pre-
dicted to be the most favorable in the absence of a sur-
rounding bumps into the helical domain immediately
beneath it, and the other two rotamers that normally are
energetically favorable bump into other local residues, as
indicated in the legend of ﬁgure 3. The mutation is pre-
dicted to disrupt the interaction between the long helix
and two strands in subdomain C, moving the domain that
holds the long helix away from domain III of EFTu 19 and
preventing it from contributing to EFTu•EFTs binding (ﬁg.
3).
To directly test whether the lack of a functional EFTs
protein was the cause of the defectivemitochondrial trans-
lation, we transduced patient ﬁbroblasts with a retroviral
vector expressing the wild-type TSFM cDNA. Since EFTs
and EFTu form a dimer in human cells, we also tested
whether overexpression of wild-type EFTu could suppress
the translation defect. Overexpression of either of these
constructs (two-to-threefold for EFTu and three-to-four-
fold for EFTs; ﬁg. 4) had a dominant negative effect on
mitochondrial translation in control cells. In independent
experiments with different control lines, global mito-
chondrial translation was 61%  18% (ﬁve independent
transductions in two control lines) of control in cells over-
expressing EFTu and 74%  14% of control in cells over-
expressing EFTs (four independent transductions in two
control lines). In the results shown in ﬁgure 1, global mi-
tochondrial translation is 68% and 75% of the control in
cells overexpressing EFTu and EFTs, respectively. A rela-
tively modest increase in global mitochondrial protein
synthesis was observed in patient cells overexpressingEFTs
compared with the appropriate control; however, there
was a signiﬁcant increase in the rate of synthesis of several
polypeptides of complex I and complex IV, and the rate
of synthesis of ATP6 and ATP8 was signiﬁcantly reduced
relative to that observed in untransduced patient ﬁbro-
blasts (table 2 and ﬁg. 1). The results were generally similar
in patient cells overexpressing EFTu. Thus, overexpression
of either translation elongation factor could partially sup-
press the translation defect in the patient cells.
To investigate the mechanism of suppression of the
translation defect by EFTu, we analyzed the steady-state
levels of the translation elongation factors by immunoblot
analysis. EFTs and EFTu in patient ﬁbroblasts were reduced
to 25% and 40% of control levels, respectively (ﬁg. 4).
Overexpression of EFTu partially rescued EFTs levels, and
EFTu levels were completely rescued by overexpression of
EFTs. Overexpression of EFTs also slightly reduced EFTu
levels in control cells. The levels of anothermitochondrial
translation elongation factor, EFG1, were unaltered in pa-
tient cells and were not changed in any of the cells over-
expressing EFTs or EFTu.
To investigate whether the increasedmitochondrial pro-
tein synthesis in patient cells overexpressing EFTu or EFTs
resulted in increased OXPHOS function, we examined the
assembly of the OXPHOS complexes by blue-native PAGE
www.ajhg.org The American Journal of Human Genetics Volume 79 November 2006 873
Figure 2. Sequence analysis of TSFM. A, DNA sequence chromatogram from a control and patient 1 (homozygous C997T) and a
heterozygous chorionic villus sample. B, Domain structure of EFTs (N-terminal in black, subdomain N in white, and subdomain C in
gray) showing the predicted Arg333Trp substitution in subdomain. C, Protein sequence alignment for Homo sapiens, Bos taurus, Cae-
norhabditis elegans, and E. coli. The alignment from human to bacteria shows that the mutated Arg333Trp is highly conserved among
different species. D, Analysis of microsatellite markers spanning the TSFM locus on chromosome 12. The markers are arbitrarily assigned
to chromosomes in both patients.
analysis (ﬁg. 5). Patient ﬁbroblasts showed reduced levels
of fully assembled complexes I, IV, and V but normal levels
of complex II and III, consistent with the deﬁciencies dem-
onstrated by enzyme activity assays (table 1). The assem-
bly of all three affected complexes was restored to control
levels (in comparison with control ﬁbroblasts overexpress-
ing the same construct) by overexpression of either elon-
gation factor (ﬁg. 5). Functional complementation of the
biochemical defect in patient cells overexpressing the
elongation factors was also demonstrated by immunoblot
analysis, which showed similar steady-state levels of both
nuclear- and mitochondrial-encoded subunits of the OX-
PHOS complexes in patient cells and controls (ﬁg. 4). In-
terestingly, overexpression of both factors led to slightly
higher steady-state levels of some complex I subunits (39
kDa, 49 kDa, and ND1) in the patient cell line compared
with controls and a markedly decreased expression of
MnSOD, the mitochondrial superoxide dismutase.
Discussion
This study ﬁrmly establishes mutations in the mitochon-
drial translation elongation factor EFTs as the cause of
disease in two unrelated patients with mitochondrial dys-
function due to a combined deﬁciency of OXPHOS en-
zymes. Several pieces of evidence support this conclusion.
Figure 3. Computational modeling based on the crystal structure of the bovine EFTu•EFTs complex. The top panel shows the structure
of the Tu•Ts dimer. Tu is on the left side of the model, and Ts is on the right. The wild-type Arg 333 residue (depicted in orange) is
superimposed on three Trp rotamers (depicted in yellow). The lower panel is a close-up of the region containing the mutation, which
shows that the Arg residue ﬁts well in front of the C-terminal side of the helix beneath it. The most favorable Trp rotamer bumps into
this same helix. The second- and third-best local minima for the Trp rotamer bump into Glu 644 and Phe 637, respectively. The second
rotamer also bumps into its own backbone.
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Figure 4. Immunoblot analysis of ﬁbroblasts from patient 1. Im-
munoblot analysis of the steady-state levels of three translation
elongation factors (EFG1, EFTu, and EFTs) and eight OXPHOS system
subunits (COI–49 kDa, COI–39 kDa, COI-ND1, COII–70 kDa, COIII-
Core1, COIV-COXI, COIV-COXIV, and COV-a) in control and patient
ﬁbroblasts before and after transduction with retroviral constructs
expressing the mitochondrial translation elongation factors EFTu
or EFTs. Porin and manganese superoxide dismutase (MnSOD) were
used as loading controls.
Figure 5. Blue-native PAGE analysis of the assembly of the OX-
PHOS complexes in patient ﬁbroblasts. Fibroblasts from patient 1
and two controls (C1 and C2) were analyzed by blue-native PAGE
before and after transduction with retroviral constructs expressing
the mitochondrial translation elongation factors EFTu or EFTs. The
gels were immunoblotted with antibodies directed against speciﬁc
individual subunits to assess the amount of each of the fully
assembled complexes.
First, pulse labeling of themitochondrial translationprod-
ucts in patient ﬁbroblasts identiﬁed a global translation
defect in both patients, leading to a failure to assemble
adequate amounts of three of the OXPHOS complexes
containing subunits encoded in mtDNA. This phenotype
could be rescued by retroviral expression of the wild-type
cDNAs for either EFTs or EFTu. Second, a homozygous
missense mutation, predicting an amino acid substitution
at an evolutionarily conserved site, was identiﬁed in TSFM
in both patients. Molecular modeling predicts that this
mutation would disrupt the Tu•Ts dimerization interface.
Finally, the steady-state levels of mutant EFTs and wild-
type EFTu were reduced in patient ﬁbroblasts, and this
phenotype was rescued by overexpression of either EFTu
or EFTs.
Much of our knowledge of the mechanism of mito-
chondrial translation in mammals comes from studies of
prokaryotic organisms, which share most of the same ini-
tiation, elongation, and termination factors.4 EFTs is a
guanine nucleotide exchange factor that binds to the
EFTu•guanosine diphosphate (GDP) complex, promoting
the release of GDP and the formation of a stable EFTu•EFTs
heterodimer. Guanosine triphosphate (GTP) then pro-
motes dissociation of EFTs from this complex, regenerat-
ing EFTu•GTP, which can then bind another aminoacyl
tRNA. This ternary complex associates with the ribosomal
A site, and, when correct codon-anticodon recognition is
established, GTP is hydrolyzed, releasing EFTu•GDP, and
the cycle repeats itself. Interestingly, not all organisms re-
quire EFTs. For instance, the budding yeast Saccaromyces
cerevisiae contains only EFTu, which can function both as
a guanosine triphosphatase and its own guanine nucleo-
tide exchange factor.23
Human TSFM maps to chromosome 12q13-q14, has an
ORF of 1,040 bp, and comprises seven exons, although it
appears that exon 5 is spliced out of the coding sequence
in the human protein. EFTs from Escherichia coli is orga-
nized into four recognizable modules: N-terminus, core
domain (consisting of subdomains N and C), coiled-coil
domain, and C-terminal domain.24 The crystal structure
of the bovine mitochondrial elongation EFTu•EFTs com-
plex has been determined to a 0.22-nm resolution,19 and
it appears to be broadly similar to that in E. coli, with a
notable exception of the virtual absence of the coiled-coil
and C-terminal domains in the mammalian protein.19 Hu-
man EFTu is 95% identical25 and human EFTs is 91% iden-
tical26 to the bovine sequence, and this permitted us to
model the effects of the homozygous Arg333Trpmutation
onto the bovine sequence without altering the backbone
structure.
Molecularmodeling predicts that themutationwill alter
the local structure of subdomain C, abolishingmost of the
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important interactions of this portion of EFTs with do-
main III of EFTu (ﬁg. 3). This is likely to lead to the de-
stabilization of the EFTu•EFTs complex and an increased
turnover of its components, explaining the decreased
steady-state levels of both factors we observed in the pa-
tient cells (ﬁg. 4). Expression of the wild-type version of
either factor would stabilize the complex, thus increasing
the total EFTu•EFTs pool. This can explain why overex-
pression of EFTu acts as a suppressor of the translation
defect in patient cells. However, the observation that over-
expression of either EFTu or EFTs in control cells acts as
a dominant negative—decreasing the rate of mitochon-
drial protein synthesis by ∼35%–40% and ∼20%–25%, re-
spectively10 (ﬁg. 1)—shows that the relative ratio of these
elongation factors is a critical determinant of mitochon-
drial translation efﬁciency. Indeed, we observed that over-
expression of EFTs slightly reduced the levels of EFTu in
control ﬁbroblasts, again suggesting that the relative ex-
pression of both factors is ﬁnely tuned. Consistent with
this interpretation, co-overexpression of both EFTu and
EFTs partially rescued the dominant negative effect of
EFTu in control ﬁbroblasts.10
It is not clear why the synthesis of the differentmtDNA-
encoded polypeptides is variably affected as a result of the
TSFM mutation, but a similar phenomenon has been ob-
served in ﬁbroblasts from patients with mutations in the
elongation factor EFG1.9,10 The most striking difference in
this study, and in patients with EFG1 mutations, is in the
synthesis of the two complex V subunits (ATP6 and ATP8),
for which the rate of synthesis is similar to the control or
even increased in the presence of the mutant elongation
factor. The most parsimonious interpretation of this ob-
servation is that the mRNA coding for these polypeptides,
a bicistronic mRNA with overlapping reading frames, can
be translated more efﬁciently than can mRNAs coding for
the other polypeptides, most of which (except ND4/4L)
are translated from monocistronic mRNAs. Whether this
difference reﬂects an increased efﬁciency of translation of
the ATP6 and ATP8 mRNA per se, or simply reduced com-
petition from other transcripts for a limited number of
ribosomes, remains uncertain, since the factors that reg-
ulate the efﬁciency of translation initiation and elonga-
tion in mitochondria are largely unknown.
The Arg333Trp TSFM mutation in patient 1 led to a fatal
mitochondrial encephalomyopathy, with muscle weak-
ness, hypotonia, rhabdomyolysis, and epilepsy as the
most prominent clinical signs and symptoms. In striking
contrast, the identical mutation in patient 2 was associ-
ated with a hypertrophic cardiomyopathy, but the results
of neurological examination and CT scan were normal.
Although tissue speciﬁcity in the clinical phenotype is
common in mitochondrial disease, as far as we are aware,
this is the ﬁrst example of a nuclear-encoded mitochon-
drial accessory factor in which the identical mutation is
associated with such a remarkable difference in clinical
presentation. In addition, in the patients with EFG1 mu-
tations, cardiac function was normal, and the only ap-
parent OXPHOS defect in this tissue was a modest reduc-
tion in the assembly of complex IV.9,10 Moreover, none of
the other study patients with combined OXPHOS enzyme
deﬁciencies presented with early-onset cardiomyopathyas
the major clinical symptom. This suggests the presence of
genetic modiﬁers, but these await identiﬁcation. Com-
bined enzyme deﬁciencies of the OXPHOS system are a
frequent cause of mitochondrial disorders. The traditional
genetic diagnostic approach in affected patients often in-
cludes the study of mitochondrial tRNAs and, more re-
cently, sequencing of the entire mitochondrial genome.
This study suggests that it will be useful to include a ge-
netic screen of nuclear-encoded translation elongation
factors in the diagnostic program for these patients or to
perform SNP genotyping in all patients originating from
consanguineous families.
Acknowledgments
We thank the support staff of the Nijmegen Centre for Mito-
chondrial Disorders for biochemical analysis of the patient skel-
etal muscle and ﬁbroblast OXPHOS-system enzyme activities. J.S.
and B.v.d.H. are currently supported by grants from the Radboud
University Medical Centre Nijmegen, the Prinses Beatrix Fonds,
and the European Union (EUMITOCOMBAT [LSHM-CT-2004-
503116] and MitoCircle). This research was supported by the Ca-
nadian Institutes of Health Research (CIHR) (to E.A.S.), by the
Israel Science Foundation (grant 1354-2005 [to O.E. and A.
Saada]), and the Israeli Ministry of Science and Technology (grant
3-904 [to O.E.]). G.V. acknowledges BioSapiens, which is funded
by the European Commission within its FP6 Programme, under
the thematic area “Life sciences, genomics and biotechnology for
health,” contract LSHG-CT-2003-503265. E.A.S. is an interna-
tional scholar of the Howard Hughes Medical Institute and a sen-
ior scientist of the CIHR.
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
BLAST, http://www.ncbi.nlm.nih.gov/BLAST/
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Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for TSFM)
POV-Ray, http://www.povray.org/
TS Modelling, http://swift.cmbi.ru.nl/gv/service/ts/
YASARA, http://www.yasara.org/
References
1. Thorburn DR (2004) Mitochondrial disorders: prevalence,
myths and advances. J Inherit Metab Dis 27:349–362
2. Smeitink J, van den Heuvel L, DiMauro S (2001) The genetics
and pathology of oxidative phosphorylation. Nat Rev Genet
2:342–352
3. Jacobs HT (2003) Disorders of mitochondrial protein synthe-
sis. Hum Mol Genet Spec No 2 12:R293–R301
www.ajhg.org The American Journal of Human Genetics Volume 79 November 2006 877
4. Spremulli LL, Coursey A, Navratil T, Hunter SE (2004) Initi-
ation and elongation factors in mammalian mitochondrial
protein biosynthesis. Prog Nucleic Acid Res Mol Biol 77:211–
261
5. Zhang Y, Spremulli LL (1998) Identiﬁcation and cloning of
human mitochondrial translational release factor 1 and the
ribosome recycling factor. Biochim Biophys Acta 1443:245–
250
6. O’Brien TW (2002) Evolution of a protein-richmitochondrial
ribosome: implications for human genetic disease. Gene 286:
73–79
7. DiMauro S, Schon EA (2003) Mitochondrial respiratory-chain
diseases. N Engl J Med 348:2656–2668
8. Taylor RW, Turnbull DM (2005) Mitochondrial DNA muta-
tions in human disease. Nat Rev Genet 6:389–402
9. Coenen MJ, Antonicka H, Ugalde C, Sasarman F, Rossi R,
Heister JG, Newbold RF, Trijbels FJ, van den Heuvel LP, Shou-
bridge EA, Smeitink JA (2004) Mutant mitochondrial elon-
gation factor G1 and combined oxidative phosphorylation
deﬁciency. N Engl J Med 351:2080–2086
10. Antonicka H, Sasarman F, Kennaway NG, Shoubridge EA
(2006) The molecular basis for tissue speciﬁcity of the oxi-
dative phosphorylation deﬁciencies in patients with muta-
tions in the mitochondrial translation factor EFG1. HumMol
Genet 15:1835–1846
11. Miller C, Saada A, Shaul N, Shabtai N, Ben-Shalom E, Shaag
A, Hershkovitz E, Elpeleg O (2004) Defective mitochondrial
translation caused by a ribosomal protein (MRPS16) muta-
tion. Ann Neurol 56:734–738
12. Lochmuller H, Johns T, Shoubridge EA (1999) Expression of
the E6 and E7 genes of human papillomavirus (HPV16) ex-
tends the life span of human myoblasts. Exp Cell Res 248:
186–193
13. Smeitink J, Sengers R, Trijbels F, van den Heuvel L (2001)
Human NADH:ubiquinone oxidoreductase. J Bioenerg Bio-
membr 33:259–266
14. Janssen AJ, Smeitink JA, van den Heuvel LP (2003) Someprac-
tical aspects of providing a diagnostic service for respiratory
chain defects. Ann Clin Biochem 40:3–8
15. Zhu Z, Yao J, Johns T, Fu K, De Bie I, Macmillan C, Cuthbert
AP, Newbold RF, Wang J, Chevrette M, Brown GK, Brown RM,
Shoubridge EA (1998) SURF1, encoding a factor involved in
the biogenesis of cytochrome c oxidase, is mutated in Leigh
syndrome. Nat Genet 20:337–343
16. Schagger H, von Jagow G (1991) Blue native electrophoresis
for isolation of membrane protein complexes in enzymati-
cally active form. Anal Biochem 199:223–231
17. Klement P, Nijtmans LG, Van den Bogert C, Houstek J (1995)
Analysis of oxidative phosphorylation complexes in cultured
human ﬁbroblasts and amniocytes by blue-native-electro-
phoresis using mitoplasts isolated with the help of digitonin.
Anal Biochem 231:218–224
18. Boulet L, Karpati G, Shoubridge EA (1992) Distribution and
threshold expression of the tRNA(Lys) mutation in skeletal
muscle of patients with myoclonic epilepsy and ragged-red
ﬁbers (MERRF). Am J Hum Genet 51:1187–1200
19. Jeppesen MG, Navratil T, Spremulli LL, Nyborg J (2005) Crys-
tal structure of the bovine mitochondrial elongation factor
Tu.Ts complex. J Biol Chem 280:5071–5081
20. Vriend G (1990) WHAT IF: a molecular modeling and drug
design program. J Mol Graph 8:52–56, 29
21. De Filippis V, Sander C, VriendG (1994) Predicting local struc-
tural changes that result from point mutations. Protein Eng
7:1203–1208
22. Andreoli C, Prokisch H, Hortnagel K, Mueller JC, Munster-
kotter M, Scharfe C, Meitinger T (2004) MitoP2, an integrated
database on mitochondrial proteins in yeast and man. Nu-
cleic Acids Res 32:D459–D462
23. Chiron S, Suleau A, Bonnefoy N (2005) Mitochondrial trans-
lation: elongation factor Tu is essential in ﬁssion yeast and
depends on an exchange factor conserved in humans but not
in budding yeast. Genetics 169:1891–1901
24. Kawashima T, Berthet-Colominas C, Wulff M, Cusack S, Le-
berman R (1996) The structure of the Escherichia coli EF-Tu.EF-
Ts complex at 2.5 resolution. Nature 379:511–518
25. Woriax VL, Burkhart W, Spremulli LL (1995) Cloning, se-
quence analysis and expression of mammalian mitochon-
drial protein synthesis elongation factor Tu. BiochimBiophys
Acta 1264:347–356
26. Xin H, Woriax V, Burkhart W, Spremulli LL (1995) Cloning
and expression ofmitochondrial translational elongation fac-
tor Ts from bovine and human liver. J Biol Chem 270:17243–
17249
